As life science companies advance beyond the first launch of commercial products, strategic focus shifts. Attention moves to expanding the business, regulatory and geographic reach of their treatments. Market expansion, label expansion, and further pipeline development create more opportunities. Companies pursue these efforts in parallel as quickly as possible.
The initial supply and operating infrastructure established to launch is often inadequate to support and sustain growth over time. Growing biopharmaceutical companies must look to close the gaps in foundational tools and processes, while scaling their business and managing the added complexity.
This info sheet details Converge’s approach to scaling and sustaining commercial growth for our clients.